US Bio CEO and CFO Execute Multi-Million Dollar Stock Cash-Out

Between May 22 and 27, United Therapeutics Corporation (UTHR) Chair and CEO Martine A. Rothblatt and CFO James Edgemond exercised stock options and sold the acquired shares on the same days in the open market, securing approximately US$5–6 million per transaction (roughly ₩7–9 billion). While Rothblatt reduced a portion of her direct holdings in the process, she still retains direct and indirect stakes worth tens of millions of dollars. Both executives’ trades were carried out under 10b5-1 trading plans adopted in November 2025, as disclosed.

According to recent filings, between June 12 and 18, CEO Rothblatt, CFO Edgemond, and the company’s general counsel each sold an additional US$5 million-plus (around ₩7 billion) of company stock. During the same period, United Therapeutics announced that the TETON-1 Phase 3 trial of Tyvaso inhalation powder for idiopathic pulmonary fibrosis met its primary endpoint. (Source: investing.com)

United Therapeutics is a U.S. biopharmaceutical firm specializing in treatments for rare, serious pulmonary diseases such as pulmonary arterial hypertension and pulmonary fibrosis. The company is also actively developing organ-replacement solutions using 3D printing and regenerative medicine technologies. Founder and CEO Martine Rothblatt is also known for founding satellite radio company SiriusXM. United Therapeutics is a publicly traded benefit corporation based in Maryland and North Carolina. (Source: en.wikipedia.org)